Prolonged treatment with the AT1 receptor blocker, XXXX , increases small and large artery compliance in uncomplicated essential @entity101 .

@entity917 @entity1 @entity101 @entity1129
BACKGROUND: Decreased arterial compliance (AC) is considered an early marker of vascular wall damage. @entity101 gradually decreases arterial compliance. We studied whether treatment with the angiotensin type 1 ( @entity1129 (1)) antagonist @entity917 will affect AC in @entity1 with essential @entity101 (EH). METHODS: Twenty-two @entity1 with EH, 6 @entity1 and 16 @entity1 , mean age 58.7 +/- 4.1 years, without overt target organ damage were included. Antihypertensive medications were withdrawn for 3 weeks, @entity917 was given at 80- and 160-mg doses. The AC, blood pressure (BP), blood, and urine were measured monthly. Large (C1) and small (C2) AC were derived from radial artery waveforms, obtained using a calibrated tonometer (model CR-2000, HDI Inc., Eagan, MN). RESULTS: After 3 months, systolic BP decreased from 172 +/- 17 to 142 +/- 13 mm Hg (P <.0001) and diastolic BP from 95 +/- 9 to 82 +/- 8 mm Hg (P <.0001). The decrease in BP was significant within 1 month and improved further on. The C1 increased by 22%, from 8.0 +/- 3.1 to 9.7 +/- 2.3 mL/mm Hg x 10 (P <.01). The C2 increased by 35%, from 2.9 +/- 1.3 to 3.9 +/- 1.9 mL/mm Hg x 100 (P <.01). Both C1 and C2 reached statistical significance only after 3 months. Systemic vascular resistance (SVR) decreased by 15% from 2,140 +/- 376 to 1,817 +/- 262 dynes/sec/cm(-5) (P <.0001). CONCLUSIONS: Treatment with @entity917 in @entity1 with EH improves small and large AC. The improvement in AC was significant only after 3 months of treatment, whereas systolic BP, diastolic BP, and SVR decreased earlier. The @entity1129 (1) receptor blockade with @entity917 seems to be an effective means of not only lowering BP but of reversal of vascular wall damage, which predisposes to cardiovascular events.
